{"protocolSection":{"identificationModule":{"nctId":"NCT05051566","orgStudyIdInfo":{"id":"17783"},"secondaryIdInfos":[{"id":"J2A-MC-GZGD","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"QSC202755","type":"OTHER","domain":"Quotient Sciences"},{"id":"2020-005750-15","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Multiple Dose Study of LY3502970 in Healthy Participants","officialTitle":"A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970"},"statusModule":{"statusVerifiedDate":"2026-04-15","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-09-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-04","type":"ACTUAL"},"completionDateStruct":{"date":"2022-04-04","type":"ACTUAL"},"studyFirstSubmitDate":"2021-09-16","studyFirstSubmitQcDate":"2021-09-16","studyFirstPostDateStruct":{"date":"2021-09-21","type":"ACTUAL"},"resultsFirstSubmitDate":"2026-04-30","resultsFirstSubmitQcDate":"2026-04-30","resultsFirstPostDateStruct":{"date":"2026-05-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-04-30","lastUpdatePostDateStruct":{"date":"2026-05-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"},"collaborators":[{"name":"Quotient Sciences","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference LY3502970 formulation. Information about safety and tolerability will be collected. The study is open to healthy participants. The study is conducted in two parts and it will last up to about 6 months, inclusive of screening period."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":26,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A","type":"EXPERIMENTAL","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 milligrams (mg), increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule once daily (QD)\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2).","interventionNames":["Drug: LY3502970"]},{"label":"Part B","type":"EXPERIMENTAL","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI 40 mg Esomeprazole tablet first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH (potential of hydrogen), and PK (pharmacokinetic) parameters were evaluated under these elevated gastric pH conditions","interventionNames":["Drug: LY3502970","Drug: Esomeprazole"]}],"interventions":[{"type":"DRUG","name":"LY3502970","description":"Administered orally.","armGroupLabels":["Part A","Part B"]},{"type":"DRUG","name":"Esomeprazole","description":"Administered orally.","armGroupLabels":["Part B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"},{"measure":"Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"},{"measure":"Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"},{"measure":"Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"},{"measure":"Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"},{"measure":"Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are overtly healthy as determined by medical evaluation.\n* Body mass index (BMI) of 18.5 to 35 kilograms per meter squared (kg/m²).\n\nExclusion Criteria:\n\n* Have an abnormal blood pressure and/or pulse rate as determined by the investigator -minor deviations acceptable to investigator are allowed\n* Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases (alanine aminotransferase \\[ALT\\] and aspartate aminotransferase \\[AST\\]) greater than 2X ULN (Upper Limit of Normal)\n* Have an abnormality in the 12-lead ECG at screening that, in the opinion of the investigator, increases the risks associated with participating in the study\n* Are women of child-bearing potential\n* Are women who are lactating","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Quotient Clinical Ltd","city":"Nottingham","zip":"NG11 6JS","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"The study was conducted in 2 parts:\n\nPart A: This is the initial formulation evaluation phase, where multiple oral doses of LY3502970 formulation prototypes were tested in a group of participants.\n\nPart B: This is the secondary evaluation phase in another group of participants, where, depending on the results of Part A, one of the prototypes may be further evaluated with regard to the effects of food, proton pump inhibitors (PPIs), or additional prototype formulations may be explored.","groups":[{"id":"FG000","title":"Part A","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule once daily (QD)\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2)."},{"id":"FG001","title":"Part B","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI (40 mg Esomeprazole tablet) first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH (potential of hydrogen), and PK parameters were evaluated under these elevated gastric pH conditions."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Received at Least 1 Dose of Study Drug (Safety Analyses Set)","achievements":[{"groupId":"FG000","comment":"* 2 mg capsule = 12\n* 4 mg capsule = 12\n* 8 mg capsule = 12\n* 16 mg reference capsule = 11\n* 16 mg prototype 1 tablet = 10\n* 16 mg prototype 2 tablet = 10","numSubjects":"12"},{"groupId":"FG001","comment":"* 2 mg capsule = 14\n* 4 mg capsule = 14\n* 8 mg capsule = 14\n* 16 mg prototype 2 tablet/Fasted = 14\n* 16 mg prototype 2 tablet/Fed = 12\n* 16 mg prototype 2 tablet + PPI = 12","numSubjects":"14"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"12"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least one dose of study drug.","groups":[{"id":"BG000","title":"Part A (LY3502970)","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule QD.\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2)."},{"id":"BG001","title":"Part B (LY3502970)","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI 40 mg Esomeprazole tablet first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH, and PK parameters were evaluated under these elevated gastric pH conditions."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"26"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"26"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"22"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"26"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"25"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","populationDescription":"All part A participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part A (LY3502970)","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule QD.\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"16 mg reference capsule (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"66.2","spread":"77.4"}]}]},{"title":"16 mg prototype 1 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":"81.2"}]}]},{"title":"16 mg prototype 2 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4","spread":"58.9"}]}]}]},{"type":"PRIMARY","title":"Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","populationDescription":"All part A participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram*hours per milliliter (ng*h/mL)","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part A (LY3502970)","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule QD.\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"16 mg reference capsule (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"988","spread":"66.9"}]}]},{"title":"16 mg prototype 1 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"1480","spread":"75.2"}]}]},{"title":"16 mg prototype 2 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"1400","spread":"51.2"}]}]}]},{"type":"PRIMARY","title":"Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).","populationDescription":"All part A participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part A (LY3502970)","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule QD.\n* Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"classes":[{"title":"16 mg reference capsule (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"7.02","lowerLimit":"4","upperLimit":"8"}]}]},{"title":"16 mg prototype 1 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"8","lowerLimit":"4","upperLimit":"16"}]}]},{"title":"16 mg prototype 2 tablet (Days 30 and 36)","categories":[{"measurements":[{"groupId":"OG000","value":"8","lowerLimit":"4","upperLimit":"16"}]}]}]},{"type":"PRIMARY","title":"Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","populationDescription":"All part B participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng/mL","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part B","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI (40 mg Esomeprazole tablet) first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH, and PK parameters were evaluated under these elevated gastric pH conditions."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"16 mg prototype 2 tablet (Fasted) (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":"32.2"}]}]},{"title":"16 mg prototype 2 tablet (Fed) (Day 30)","categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":"29.6"}]}]},{"title":"16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)","categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"51.0"}]}]}]},{"type":"PRIMARY","title":"Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","populationDescription":"All part B participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng*h/mL","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part B","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI (40 mg Esomeprazole tablet) first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH, and PK parameters were evaluated under these elevated gastric pH conditions."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"16 mg prototype 2 tablet (Fasted) (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"903","spread":"25.3"}]}]},{"title":"16 mg prototype 2 tablet (Fed) (Day 30)","categories":[{"measurements":[{"groupId":"OG000","value":"865","spread":"24.6"}]}]},{"title":"16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)","categories":[{"measurements":[{"groupId":"OG000","value":"956","spread":"40.1"}]}]}]},{"type":"PRIMARY","title":"Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation","description":"Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.","populationDescription":"All part B participants who received at least 1 dose of study drug and had evaluable PK data for this outcome.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)","groups":[{"id":"OG000","title":"Part B","description":"* Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received daily doses of LY3502970 oral capsule, with the dose escalation every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19.\n* Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD.\n* Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI (40 mg Esomeprazole tablet) first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH, and PK parameters were evaluated under these elevated gastric pH conditions."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"title":"16 mg prototype 2 tablet (Fasted) (Day 24)","categories":[{"measurements":[{"groupId":"OG000","value":"8.00","lowerLimit":"4.00","upperLimit":"12.00"}]}]},{"title":"16 mg prototype 2 tablet (Fed) (Day 30)","categories":[{"measurements":[{"groupId":"OG000","value":"7.00","lowerLimit":"2.00","upperLimit":"16.05"}]}]},{"title":"16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)","categories":[{"measurements":[{"groupId":"OG000","value":"7.00","lowerLimit":"4.00","upperLimit":"12.00"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Baseline to the end of follow-up (up to Day 53)","description":"All participants from the safety analyses set.","eventGroups":[{"id":"EG000","title":"Part A - 2 mg Capsule","description":"Part A participants who received 2 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG001","title":"Part A - 4 mg Capsule","description":"Part A participants who received 4 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG002","title":"Part A - 8 mg Capsule","description":"Part A participants who received 8 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":11,"otherNumAtRisk":12},{"id":"EG003","title":"Part A - 16 mg Capsule","description":"Part A participants who received 16 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11},{"id":"EG004","title":"Part A - 16 mg Prototype 1 Tablet","description":"Part A participants who received 16 mg LY3502970 prototype 1 tablet were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":9,"otherNumAtRisk":10},{"id":"EG005","title":"Part A - 16 mg Prototype 2 Tablet","description":"Part A participants who received 16 mg LY3502970 prototype 2 tablet were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":8,"otherNumAtRisk":10},{"id":"EG006","title":"Part B - 2 mg Capsule","description":"Part B participants who received 2 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":13,"otherNumAtRisk":14},{"id":"EG007","title":"Part B - 4 mg Capsule","description":"Part B participants who received 4 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":12,"otherNumAtRisk":14},{"id":"EG008","title":"Part B - 8 mg Capsule","description":"Part B participants who received 8 mg LY3502970 capsule were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":13,"otherNumAtRisk":14},{"id":"EG009","title":"Part B -16 mg Prototype 2 Tablet/Fasted","description":"Part B participants who received 16 mg LY3502970 prototype 2 tablet in fasted stage were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":12,"otherNumAtRisk":14},{"id":"EG010","title":"Part B - 16 mg Prototype 2 Tablet/Fed","description":"Part B participants who received 16 mg LY3502970 prototype 2 tablet in fed stage were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":8,"otherNumAtRisk":12},{"id":"EG011","title":"Part B - 16 mg Prototype 2 Tablet + PPI","description":"Part B participants who received 16 mg LY3502970 prototype 2 tablet together with PPI Esomeprazole in fasted stage were grouped in this arm.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":8,"otherNumAtRisk":12}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG009","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":7,"numAffected":7,"numAtRisk":14},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Epigastric discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lip dry","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lip swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":12},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":12},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":12},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":11},{"groupId":"EG004","numEvents":10,"numAffected":5,"numAtRisk":10},{"groupId":"EG005","numEvents":7,"numAffected":6,"numAtRisk":10},{"groupId":"EG006","numEvents":7,"numAffected":7,"numAtRisk":14},{"groupId":"EG007","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG009","numEvents":4,"numAffected":4,"numAtRisk":14},{"groupId":"EG010","numEvents":4,"numAffected":3,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Paraesthesia oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hunger","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Covid-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG009","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":6,"numAffected":6,"numAtRisk":14},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Muscle twitching","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":3,"numAffected":2,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":12},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":12},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":4,"numAffected":4,"numAtRisk":14},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":6,"numAffected":4,"numAtRisk":14},{"groupId":"EG010","numEvents":3,"numAffected":1,"numAtRisk":12},{"groupId":"EG011","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Ketonuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Polyuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Cold sweat","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Excessive cerumen production","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-01-31","uploadDate":"2026-04-16T21:29","filename":"Prot_000.pdf","size":4783725},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-10-05","uploadDate":"2026-04-16T21:30","filename":"SAP_001.pdf","size":7728843}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"interventionBrowseModule":{"meshes":[{"id":"C000729680","term":"orforglipron"},{"id":"D064098","term":"Esomeprazole"}],"ancestors":[{"id":"D009853","term":"Omeprazole"},{"id":"D053799","term":"2-Pyridinylmethylsulfinylbenzimidazoles"},{"id":"D013454","term":"Sulfoxides"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D011725","term":"Pyridines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D001562","term":"Benzimidazoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":true}